Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the acquisition of EGFR second-site mutations and other mechanisms, which necessitates alternative therapies. Dacomiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Poels, Kamrine E., Schoenfeld, Adam J., Makhnin, Alex, Tobi, Yosef, Wang, Yuli, Frisco-Cabanos, Heidie, Chakrabarti, Shaon, Shi, Manli, Napoli, Chelsi, McDonald, Thomas O., Tan, Weiwei, Hata, Aaron, Weinrich, Scott L., Yu, Helena A., Michor, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211846/
https://www.ncbi.nlm.nih.gov/pubmed/34140482
http://dx.doi.org/10.1038/s41467-021-23912-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211846/
https://www.ncbi.nlm.nih.gov/pubmed/34140482
http://dx.doi.org/10.1038/s41467-021-23912-4

Ejemplares similares